---
title: "Guanhao Biotech released its Q1 2025 performance, with a net profit attributable to the parent company of 14.8661 million yuan, a year-on-year increase of 3.3%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237016045.md"
description: "Guanhao Biotech released its Q1 2025 performance, with operating revenue of 94.7971 million yuan, a year-on-year increase of 3.67%; net profit attributable to the parent company of 14.8661 million yuan, a year-on-year increase of 3.3%; net profit excluding non-recurring gains and losses of 13.8657 million yuan, a year-on-year decrease of 0.73%; basic earnings per share of 0.06 yuan/share"
datetime: "2025-04-22T16:01:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237016045.md)
  - [en](https://longbridge.com/en/news/237016045.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237016045.md)
generator: "portal-rs"
---

# Guanhao Biotech released its Q1 2025 performance, with a net profit attributable to the parent company of 14.8661 million yuan, a year-on-year increase of 3.3%

According to the Zhitong Finance APP, Guanhao Biotech (300238.SZ) released its first quarter report for 2025. The company's operating revenue for the first quarter of 2025 was 94.7971 million yuan, a year-on-year increase of 3.67%; the net profit attributable to shareholders of the listed company was 14.8661 million yuan, a year-on-year increase of 3.30%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.8657 million yuan, a year-on-year decrease of 0.73%; basic earnings per share were 0.06 yuan/share

### Related Stocks

- [300238.CN](https://longbridge.com/en/quote/300238.CN.md)

## Related News & Research

- [Canada minister says he welcomes US clarification on French language requirements](https://longbridge.com/en/news/297196718.md)
- [Germany's Merz urges EU to keep long-term budget affordable](https://longbridge.com/en/news/297184642.md)
- [Heidelberg Pharma says China NMPA clears HDP-101 combo trial in multiple myeloma](https://longbridge.com/en/news/297070749.md)
- [AFYREN scales bio-based acid output and strengthens climate-resilient positioning](https://longbridge.com/en/news/297214424.md)
- [FFARMS: Drought and low commodity prices led to a sharp half-year loss despite higher turnover](https://longbridge.com/en/news/296997353.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**